main product
Chimeric Virus
clinical-phase
pharmaceutical company
pharma company
Treatment of HPV infections
treatment of cervical dysplasia
Human Papilloma Virus
proprietary technological platform
immunotherapeutic vaccine
infectious viral particles capable
Cervical Dysplasia VLPbio
Infectious Bursal Disease Virus
cases of cervical lesions
biotechnological company
viral infection
Cervivax
diligence phase
proprietary Ch-VLP platform
unmet clinical needs
efficacy proof of concept
main pharmaceutical markets
New Generation Therapeutic vaccine
terms of efficacy
proofs of concept
unmet need
larger biotech
large biotech
immunotherapeutic solutionsto fight
commercial therapeutic solutions
leading pharma companies
antigens
animal diseases
innovative vaccines
order
absence
immunogenic studies
development
preliminary agreements
therapies
IBDV
current status
different pathologies
excellent results
cellular immune response
business model
kind of responses
prophylactic approaches
overall aim
project
surgery
adyuvant
technology
world
chemotherapy
potential